2017

1. CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial

   Annals of Oncology, Vol. 28, pp. x94

2. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

   The Lancet Haematology, Vol. 4, Núm. 8, pp. e362-e373